Flag­ship’s Sig­ilon grabs $80M to bring Robert Langer cell ther­a­py tech in­to the clin­ic

Roge­rio Vi­val­di had nev­er giv­en much thought to in­dus­try.

A new­ly mint­ed MD, he was work­ing at a hos­pi­tal in Rio De Janeiro when one of his pro­fes­sors asked if he might take on a case that re­quired con­sis­tent fol­low-up: A 14-year-old boy with Gauch­er’s, a rare ge­net­ic dis­or­der that meant he was miss­ing a key en­zyme of­ten called the cell’s re­cy­cling sys­tem. He had come in with en­larged or­gans and stunt­ed growth.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.